ArticleInternational cancer conference journal2019

Erlotinib and bevacizumab combination therapy for afatinib-refractory leptomeningeal carcinomatosis from EGFR-mutated lung cancer.

Miyuki Abe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.